0000899243-18-016821.txt : 20180615 0000899243-18-016821.hdr.sgml : 20180615 20180615175124 ACCESSION NUMBER: 0000899243-18-016821 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180613 FILED AS OF DATE: 20180615 DATE AS OF CHANGE: 20180615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROWLAND LLOYD A CENTRAL INDEX KEY: 0001236395 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 18903242 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-06-13 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001236395 ROWLAND LLOYD A C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 General Counsel Stock Option (right to buy) 25.67 2028-05-30 Common Stock 100000 D The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on May 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. /s/ Lloyd Rowland 2018-06-15